Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

DMAC vs RGNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DMAC Captures Overall Composite Edge (46.3 HOLD vs 40.0 SELL), While RGNX Leads 4–2 on Growth & Valuation Pillars

DMAC Overall Winner 6-Pillar Tally: DMAC 2 – 4 RGNX Matrix Metrics: DMAC 5 – 2 RGNX

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (46.3/100 HOLD vs. 40.0/100 SELL) after splitting the core matrix 5–2 (led by Growth & Scale, Profitability & Quality), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus RGNX at $7.47 (N/M Forward P/E, -120.4% operating margin).

  • Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. RGNX 40.0/100 SELL) and 1.74β · 98% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 50.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DMAC vs RGNX
DMAC NASDAQ Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$8.41
-4.27% 1D
Market Cap $503.1M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.74β · 98% Vol
Unified Composite Score
46.3 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 65.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.0 · SMA20: $9.24 · SMA50: $8.24
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
40.0 / 100 SELL
Tech 15.0 Fund 50.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 50
RSI-14: 50.0 · SMA20: $7.42 · SMA50: $7.63

6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 4 RGNX)

Columns: Metric · DMAC · RGNX
1. Valuation Multiples RGNX
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M 0.26x
EV / Revenue N/M 3.1x
2. Growth & Scale DMAC
Revenue Growth (YoY) +0.0% -69.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $154M
Market Cap $503.1M $500.9M
3. Profitability & Quality DMAC
Gross Margin N/A -64.5%
Operating Margin 0.0% -120.4%
Net Profit Margin 0.0% -113.9%
Return on Equity (ROE) -114.6% -113.2%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$32M -$155M
Cash Flow Margin N/A -100.6%
Net Cash / Leverage $4.9M Net Cash $29M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning RGNX
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 106.3% (14th %ile) 349.6% (52nd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Distribution
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity N/A 55.9% of Rev ($86M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DMAC (5) vs RGNX (2)
Institutional Metric DMAC RGNX Criterion Row Edge
Market Capitalization
Scale
$503.1M $500.9M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% -69.2% Higher Growth DMAC
Operating Margin (TTM)
Profitability
0.0% -120.4% Higher Margin DMAC
Net Profit Margin
Profitability
0.0% -113.9% Higher Margin DMAC
Return on Equity (ROE)
Capital Efficiency
-114.6% -113.2% Higher ROE RGNX
52-Week Range Position
Momentum
55% ($5–$11) 19% ($5–$16) Stronger Trend DMAC
Beta / 30D Volatility
Risk Regime
1.74β · 98% Vol 1.81β · 76% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
46.3 / 100 (HOLD) 40.0 / 100 (SELL) Higher Composite DMAC
Trailing 12M Revenue (USD)
Operating Scale
N/A $154M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A -64.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.26x PEG · 3.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$32M ($4.9M Net Cash) -$155M ($29M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DMAC +3.29 pp
DMAC: +11.16% · RGNX: +7.87%
3M Horizon DMAC +59.83 pp
DMAC: +27.31% · RGNX: -32.52%
6M Horizon DMAC +15.94 pp
DMAC: +48.15% · RGNX: +32.21%
1Y Horizon DMAC +91.08 pp
DMAC: +55.26% · RGNX: -35.82%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DMAC Revenue RGNX Revenue DMAC Op. Margin RGNX Op. Margin Margin Leader
FY2018 $0M $220M -1352.2% 40.3% RGNX
FY2019 N/A $40M N/A -422.9% RGNX
FY2020 N/A $150M N/A -77.1% RGNX
FY2021 N/A $470M N/A 34.0% RGNX
FY2022 N/A $110M N/A -233.2% RGNX
FY2023 N/A $90M N/A -297.1% RGNX
FY2024 N/A $80M N/A -280.0% RGNX
FY2025 N/A $170M N/A -94.6% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DMAC SURGE
8d in phase · OBV NEUTRAL
Current IV 106.3%
IV Percentile 14th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DMAC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $503.1M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published

Investor FAQ DMAC vs RGNX Key Questions & Quantitative Answers

As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over REGENXBIO Inc. (RGNX) on higher Unified Composite conviction (46.3/100 HOLD vs. 40.0/100 SELL) after splitting the core matrix 5–2 (led by Growth & Scale, Profitability & Quality), while RGNX wins 4–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus RGNX at $7.47 (N/M Forward P/E, -120.4% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. RGNX 40.0/100 SELL) and 1.74β · 98% Vol risk profile, whereas RGNX leads top-line expansion (-69.2% YoY revenue growth, 0.26x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 46.0); meanwhile RGNX is in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 50.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DMAC leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RGNX at -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while RGNX shifted -22.7%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus 55.9% of Rev ($86M) (0 disclosures) for RGNX.

RGNX screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus RGNX (-113.2% ROE) capital efficiency.

In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.